The chemokine monocyte chemoattractant protein-1/CCL2 is a promoter of breast cancer metastasis.
Breast cancer
chemokine receptors
chemokines
macrophages
metastasis
Journal
Cellular & molecular immunology
ISSN: 2042-0226
Titre abrégé: Cell Mol Immunol
Pays: China
ID NLM: 101242872
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
04
10
2022
accepted:
17
03
2023
medline:
3
7
2023
pubmed:
20
5
2023
entrez:
19
5
2023
Statut:
ppublish
Résumé
Breast cancer is the most prevalent cancer worldwide, and metastasis is the leading cause of death in cancer patients. Human monocyte chemoattractant protein-1 (MCP-1/CCL2) was isolated from the culture supernatants of not only mitogen-activated peripheral blood mononuclear leukocytes but also malignant glioma cells based on its in vitro chemotactic activity toward human monocytes. MCP-1 was subsequently found to be identical to a previously described tumor cell-derived chemotactic factor thought to be responsible for the accumulation of tumor-associated macrophages (TAMs), and it became a candidate target of clinical intervention; however, the role of TAMs in cancer development was still controversial at the time of the discovery of MCP-1. The in vivo role of MCP-1 in cancer progression was first evaluated by examining human cancer tissues, including breast cancers. Positive correlations between the level of MCP-1 production in tumors and the degree of TAM infiltration and cancer progression were established. The contribution of MCP-1 to the growth of primary tumors and metastasis to the lung, bone, and brain was examined in mouse breast cancer models. The results of these studies strongly suggested that MCP-1 is a promoter of breast cancer metastasis to the lung and brain but not bone. Potential mechanisms of MCP-1 production in the breast cancer microenvironment have also been reported. In the present manuscript, we review studies in which the role of MCP-1 in breast cancer development and progression and the mechanisms of its production were examined and attempt to draw a consensus and discuss the potential use of MCP-1 as a biomarker for diagnosis.
Identifiants
pubmed: 37208442
doi: 10.1038/s41423-023-01013-0
pii: 10.1038/s41423-023-01013-0
pmc: PMC10310763
doi:
Substances chimiques
Chemokine CCL2
0
CCL2 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
714-738Informations de copyright
© 2023. The Author(s).
Références
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Cancer Res. 2012 Jun 1;72(11):2768-79
pubmed: 22472119
Breast Cancer Res. 2017 Mar 2;19(1):21
pubmed: 28253895
Cancer Metastasis Rev. 2021 Jun;40(2):447-476
pubmed: 33959849
J Immunol. 1993 Sep 15;151(6):3292-8
pubmed: 8376779
Pathol Res Pract. 1998;194(5):335-40
pubmed: 9651946
Cancer Sci. 2020 Jan;111(1):47-58
pubmed: 31710162
Cell Death Dis. 2022 Aug 29;13(8):748
pubmed: 36038549
Pharm Res. 1995 Nov;12(11):1598-604
pubmed: 8592656
Int J Biochem Cell Biol. 2004 Apr;36(4):568-84
pubmed: 15010324
Nat Rev Cancer. 2015 Feb;15(2):96-109
pubmed: 25614008
Breast Cancer Res Treat. 2015 Apr;150(2):309-20
pubmed: 25744294
J Neural Transm (Vienna). 2018 Dec;125(12):1781-1786
pubmed: 30284076
BMC Cancer. 2017 Jan 31;17(1):88
pubmed: 28143493
Immunol Lett. 1999 May 3;68(1):141-6
pubmed: 10397169
Int J Cancer. 2009 Sep 15;125(6):1276-84
pubmed: 19479998
Front Cell Dev Biol. 2021 Jun 24;9:657158
pubmed: 34249913
Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12053-8
pubmed: 9342361
Breast Cancer Res. 2000;2(5):331-4
pubmed: 11250725
J Exp Med. 2001 Mar 19;193(6):727-40
pubmed: 11257139
Cancer Sci. 2020 Mar;111(3):924-931
pubmed: 31943636
Cancer Res. 2006 Jul 15;66(14):7176-84
pubmed: 16849564
Int J Mol Sci. 2018 Jul 24;19(8):
pubmed: 30042333
Diabetes. 2010 Mar;59(3):564-71
pubmed: 20007935
Cell Mol Life Sci. 2015 Sep;72(17):3253-66
pubmed: 26001902
Virchows Arch. 2019 Jan;474(1):3-12
pubmed: 30368555
BMC Cancer. 2011 Apr 12;11:130
pubmed: 21486440
Sci Rep. 2022 Nov 8;12(1):19026
pubmed: 36347994
Nature. 2015 Nov 5;527(7576):100-104
pubmed: 26479035
J Biol Chem. 2012 Oct 19;287(43):36593-608
pubmed: 22927430
J Clin Invest. 2015 Feb;125(2):621-35
pubmed: 25555218
Science. 2008 Jan 11;319(5860):195-8
pubmed: 18187653
Pharmacol Rev. 2000 Mar;52(1):145-76
pubmed: 10699158
Int Immunopharmacol. 2021 Dec;101(Pt B):107598
pubmed: 34233864
Breast Cancer Res. 2022 Sep 12;24(1):60
pubmed: 36096830
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82
pubmed: 1359541
Oncotarget. 2016 May 10;7(19):28697-710
pubmed: 26885690
Int J Cancer. 2006 Jan 1;118(1):35-42
pubmed: 16003740
Science. 2002 Nov 1;298(5595):1039-43
pubmed: 12351676
J Immunol. 2009 Sep 1;183(5):3463-71
pubmed: 19641140
Immunol Today. 1992 Jul;13(7):265-70
pubmed: 1388654
Oncologist. 2016 Apr;21(4):404-17
pubmed: 26865587
Front Immunol. 2016 Jan 20;7:2
pubmed: 26834744
Int J Mol Sci. 2023 Jan 11;24(2):
pubmed: 36674955
Gastroenterology. 2015 Oct;149(4):1053-67.e14
pubmed: 26065367
Pharmacol Res. 2015 Oct;100:266-70
pubmed: 26275794
Cancer Discov. 2017 Nov;7(11):1320-1335
pubmed: 28790030
Curr Pharm Biotechnol. 2016;17(6):486-94
pubmed: 26927216
Cancer Immunol Immunother. 2000 May;49(2):63-70
pubmed: 10823415
J Exp Med. 2015 Jun 29;212(7):1043-59
pubmed: 26056232
Cancers (Basel). 2019 Feb 05;11(2):
pubmed: 30764547
Int J Cancer. 1997 Apr 10;71(2):257-66
pubmed: 9139852
J Cancer. 2017 Sep 12;8(16):3131-3141
pubmed: 29158785
Nat Rev Dis Primers. 2020 Oct 15;6(1):83
pubmed: 33060614
Immunity. 2021 May 11;54(5):859-874
pubmed: 33838745
Breast Cancer Res Treat. 2001 Jan;65(2):101-10
pubmed: 11261825
J Clin Invest. 1995 May;95(5):2391-6
pubmed: 7738202
J Natl Cancer Inst. 2015 Jun 03;107(8):
pubmed: 26041837
Clin Exp Metastasis. 2008;25(5):517-29
pubmed: 18340424
Mol Cell Biol. 1991 Jun;11(6):3125-31
pubmed: 2038321
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
J Immunol. 2003 Apr 15;170(8):4139-47
pubmed: 12682245
PLoS One. 2009 Aug 10;4(8):e6562
pubmed: 19668347
Immunobiology. 2018 Feb;223(2):151-161
pubmed: 29107385
Br J Surg. 2000 Aug;87(8):992-1005
pubmed: 10931041
Oncogene. 2020 Mar;39(11):2275-2289
pubmed: 31827233
PLoS One. 2014 Aug 26;9(8):e105545
pubmed: 25157401
Int J Mol Sci. 2020 Nov 27;21(23):
pubmed: 33260837
Clin Exp Metastasis. 2009;26(7):817-28
pubmed: 19629725
QJM. 2023 May 27;116(5):345-354
pubmed: 36592055
Nat Commun. 2021 Nov 25;12(1):6889
pubmed: 34824220
Med Hypotheses. 2021 Nov 9;158:110734
pubmed: 34861532
Cancer Cell. 2008 Jan;13(1):58-68
pubmed: 18167340
Cell Rep. 2015 Nov 3;13(5):1046-58
pubmed: 26565916
Ann Transl Med. 2020 Apr;8(7):482
pubmed: 32395526
Breast Cancer (Auckl). 2015 Sep 01;9(Suppl 1):23-34
pubmed: 26380552
Cancers (Basel). 2015 Jan 15;7(1):143-78
pubmed: 25599228
Cancer Res. 2010 May 15;70(10):4102-11
pubmed: 20442283
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):365-70
pubmed: 11756660
Cancer Res. 2013 Jan 15;73(2):662-71
pubmed: 23329645
Cancer Immunol Immunother. 1995 Oct;41(4):227-35
pubmed: 7489565
Cancer Lett. 2018 Nov 28;437:25-34
pubmed: 30165193
Cell Oncol (Dordr). 2020 Feb;43(1):1-18
pubmed: 31900901
Breast Cancer Res Treat. 2012 Jan;131(2):401-11
pubmed: 21344235
Cold Spring Harb Perspect Biol. 2011 Jan 01;3(1):a003277
pubmed: 20810549
J Neurosurg. 1994 Jun;80(6):1056-62
pubmed: 8189261
Br J Cancer. 2021 Jul;125(2):164-175
pubmed: 33824479
Nat Commun. 2018 Jan 2;9(1):21
pubmed: 29295986
Cell Oncol (Dordr). 2015 Jun;38(3):227-35
pubmed: 25869021
Cancer Res. 1978 Oct;38(10):3174-81
pubmed: 210930
Proc Natl Acad Sci U S A. 1987 Dec;84(24):9233-7
pubmed: 3480540
Immunity. 2000 Feb;12(2):121-7
pubmed: 10714678
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
Anticancer Res. 1991 Jul-Aug;11(4):1509-15
pubmed: 1746907
Front Immunol. 2019 Feb 27;10:333
pubmed: 30873179
Front Pharmacol. 2022 Jun 13;13:920779
pubmed: 35770088
J Interferon Cytokine Res. 2001 Jun;21(6):389-98
pubmed: 11440636
Genome Biol. 2010;11(3):R25
pubmed: 20196867
Nature. 2014 Nov 6;515(7525):130-3
pubmed: 25337873
Int J Cancer. 1998 Jul 17;77(2):306-13
pubmed: 9650569
PLoS One. 2013;8(3):e58791
pubmed: 23527025
Cell Mol Immunol. 2018 Apr;15(4):335-345
pubmed: 29375123
Breast Cancer Res. 2017 Jan 11;19(1):4
pubmed: 28077158
Stem Cell Res Ther. 2015 May 01;6:87
pubmed: 25928089
PLoS One. 2016 Nov 7;11(11):e0165595
pubmed: 27820834
Cell Commun Signal. 2022 Jun 17;20(1):92
pubmed: 35715860
Curr Issues Mol Biol. 2021 Oct 22;43(3):1726-1740
pubmed: 34698088
Int J Mol Sci. 2021 Aug 08;22(16):
pubmed: 34445235
Sci Rep. 2021 Jul 8;11(1):14120
pubmed: 34239022
J Pathol. 1994 Mar;172(3):229-35
pubmed: 8195926
Transl Oncol. 2017 Oct;10(5):734-743
pubmed: 28734227
Clin Cancer Res. 2000 Aug;6(8):3282-9
pubmed: 10955814
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Clin Exp Metastasis. 2005;22(1):47-59
pubmed: 16132578
Cell. 2020 Jun 11;181(6):1346-1363.e21
pubmed: 32473126
Clin Cancer Res. 2007 Sep 1;13(17):5020-7
pubmed: 17785552
Breast Cancer Res. 2009;11(1):202
pubmed: 19291273
Nat Cell Biol. 2019 Sep;21(9):1113-1126
pubmed: 31451770
J Exp Med. 1989 Apr 1;169(4):1449-59
pubmed: 2926329
Adv Exp Med Biol. 2021;1287:183-200
pubmed: 33034033
Ann Surg Oncol. 2012 Mar;19(3):935-40
pubmed: 21879270
Breast Cancer Res. 2007;9(1):R15
pubmed: 17261184
PLoS One. 2015 Mar 20;10(3):e0121281
pubmed: 25793264
Front Cell Dev Biol. 2020 Jan 31;8:25
pubmed: 32083079
J Exp Med. 1990 Jun 1;171(6):2177-82
pubmed: 2161898
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Neoplasia. 2014 Nov 20;16(11):950-60
pubmed: 25425969
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Semin Immunol. 2021 Oct;57:101538
pubmed: 34876331
Cancer. 1952 Sep;5(5):979-91
pubmed: 12988187
Breast Cancer Res Treat. 2015 Apr;150(2):255-63
pubmed: 25721605
EMBO Mol Med. 2017 Jun;9(6):852
pubmed: 28572088
Ann Med. 1995 Feb;27(1):79-85
pubmed: 7742005
Immunity. 2012 May 25;36(5):705-16
pubmed: 22633458
Nature. 2015 Apr 16;520(7547):358-62
pubmed: 25855289
Breast Cancer Res. 2011 Aug 12;13(4):215
pubmed: 21884641
Oncogene. 2000 Feb 24;19(9):1123-31
pubmed: 10713699
Cell. 1983 Jul;33(3):939-47
pubmed: 6872001
Med Oncol. 2015 Nov;32(11):254
pubmed: 26487662
Int J Mol Sci. 2019 Dec 16;20(24):
pubmed: 31888216
Nat Cell Biol. 2013 Mar;15(3):284-94
pubmed: 23396050
Eur Rev Med Pharmacol Sci. 2013 Mar;17(5):596-608
pubmed: 23543442
Nat Commun. 2021 Jun 10;12(1):3543
pubmed: 34112803
Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24
pubmed: 25027649
J Clin Invest. 1997 Nov 15;100(10):2552-61
pubmed: 9366570
Cancer Metastasis Rev. 2006 Sep;25(3):409-16
pubmed: 16951987
J Natl Cancer Inst. 1993 Nov 17;85(22):1836-9
pubmed: 8230263
Semin Cancer Biol. 2019 Dec;59:66-79
pubmed: 30738865
Biomed Res Int. 2018 Jul 30;2018:2124390
pubmed: 30151375
Cancer Cell. 2011 Sep 13;20(3):300-14
pubmed: 21907922
Exp Cell Res. 2011 Mar 10;317(5):674-84
pubmed: 21056554
Cell. 2018 Jan 25;172(3):393-407
pubmed: 29373828
Lancet. 2017 Mar 18;389(10074):1134-1150
pubmed: 27865536
Hum Pathol. 2008 Feb;39(2):167-74
pubmed: 18045647
Cancer Lett. 2021 Feb 28;499:148-163
pubmed: 33253790
Mol Cancer Res. 2018 Feb;16(2):296-308
pubmed: 29133591
Oncoimmunology. 2013 Jul 1;2(7):e25474
pubmed: 24073384
Proc Natl Acad Sci U S A. 1987 Aug;84(16):5763-7
pubmed: 3039506
Int J Cancer. 1990 Apr 15;45(4):795-7
pubmed: 2182547
Breast Cancer Res Treat. 2018 Aug;170(3):477-486
pubmed: 29594759
Breast Cancer Res Treat. 2011 Feb;125(3):715-27
pubmed: 20369284
Comput Struct Biotechnol J. 2021 Jul 18;19:4101-4109
pubmed: 34527184
J Exp Med. 1998 Feb 16;187(4):601-8
pubmed: 9463410
Sci Rep. 2021 Apr 22;11(1):8708
pubmed: 33888841
Mol Cell Biol. 1992 Mar;12(3):954-61
pubmed: 1312220
Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):
pubmed: 34518219
Cancer. 2001 Sep 1;92(5):1085-91
pubmed: 11571719
PLoS One. 2017 Apr 25;12(4):e0175558
pubmed: 28441391
Sci Rep. 2018 Jun 22;8(1):9575
pubmed: 29934505
J Cancer Res Clin Oncol. 2005 Jul;131(7):453-8
pubmed: 15883814
Science. 2009 Jul 31;325(5940):612-6
pubmed: 19644120
Front Immunol. 2019 Apr 12;10:757
pubmed: 31031757
J Cell Biochem. 1983;21(2):151-9
pubmed: 6309875
Int J Clin Exp Med. 2015 Sep 15;8(9):15684-91
pubmed: 26629063
Cancer Res. 2015 Mar 15;75(6):950-62
pubmed: 25736687
Biomol Concepts. 2014 Aug;5(4):265-73
pubmed: 25372758
J Immunol. 1989 Mar 15;142(6):1956-62
pubmed: 2921521
Clin Cancer Res. 2015 Aug 15;21(16):3794-805
pubmed: 25901081
Nat Rev Cancer. 2022 Jan;22(1):25-44
pubmed: 34671117
Cancer Med. 2020 Nov;9(21):8074-8085
pubmed: 33026171
J Clin Invest. 2017 Dec 1;127(12):4498-4515
pubmed: 29130936
Cancer Res. 1992 Mar 15;52(6):1399-405
pubmed: 1540948
Curr Drug Targets. 2010 Sep;11(9):1133-46
pubmed: 20545607
Clin Chem. 2005 Feb;51(2):452-5
pubmed: 15681563
J Immunol. 2007 Sep 1;179(5):2851-9
pubmed: 17709499
J Clin Invest. 2021 Oct 15;131(20):
pubmed: 34520398
Biochem Biophys Res Commun. 1999 Jun 7;259(2):344-8
pubmed: 10362511
J Neurosurg. 1995 May;82(5):874-8
pubmed: 7714614
Oncogene. 2021 Sep;40(39):5854-5865
pubmed: 34345015
Tumour Biol. 2004 Jan-Apr;25(1-2):14-7
pubmed: 15192307
Exp Cell Res. 2017 Feb 1;351(1):100-108
pubmed: 28077301
Mol Cancer Res. 2019 Feb;17(2):604-617
pubmed: 30446625
J Hematol Oncol. 2017 Feb 28;10(1):58
pubmed: 28241846
Theranostics. 2020 Apr 27;10(13):5687-5703
pubmed: 32483412
Int J Cancer. 1991 Sep 30;49(3):431-5
pubmed: 1655661
Nat Rev Cancer. 2009 May;9(5):361-71
pubmed: 19343034
Cancers (Basel). 2021 Dec 16;13(24):
pubmed: 34944943